Bellevue Asset Management LLC trimmed its holdings in Johnson & Johnson (NYSE:JNJ) by 24.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,807 shares of the company’s stock after selling 600 shares during the quarter. Bellevue Asset Management LLC’s holdings in Johnson & Johnson were worth $269,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also bought and sold shares of the company. Newfound Research LLC bought a new position in Johnson & Johnson in the third quarter worth $28,000. Islay Capital Management LLC acquired a new position in Johnson & Johnson during the second quarter worth $42,000. FAI Wealth Management increased its stake in shares of Johnson & Johnson by 45.9% in the second quarter. FAI Wealth Management now owns 321 shares of the company’s stock valued at $45,000 after buying an additional 101 shares in the last quarter. SeaBridge Investment Advisors LLC increased its stake in shares of Johnson & Johnson by 160.0% in the second quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock valued at $46,000 after buying an additional 200 shares in the last quarter. Finally, Crewe Advisors LLC increased its stake in shares of Johnson & Johnson by 909.1% in the third quarter. Crewe Advisors LLC now owns 333 shares of the company’s stock valued at $50,000 after buying an additional 300 shares in the last quarter. 67.44% of the stock is owned by institutional investors.
JNJ has been the subject of a number of research reports. Raymond James restated a “buy” rating on shares of Johnson & Johnson in a research note on Friday, November 20th. Cantor Fitzgerald lifted their price objective on Johnson & Johnson from $168.00 to $180.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 14th. ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Monday, August 3rd. Stifel Nicolaus lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Finally, Credit Suisse Group lifted their price objective on Johnson & Johnson from $163.00 to $168.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 14th. One analyst has rated the stock with a sell rating, four have given a hold rating and ten have given a buy rating to the stock. Johnson & Johnson has a consensus rating of “Buy” and an average target price of $164.93.
NYSE:JNJ opened at $143.68 on Friday. Johnson & Johnson has a fifty-two week low of $109.16 and a fifty-two week high of $157.00. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.48 and a quick ratio of 1.24. The stock has a market capitalization of $378.24 billion, a PE ratio of 22.59, a price-to-earnings-growth ratio of 3.04 and a beta of 0.69. The business’s 50-day simple moving average is $145.31 and its 200-day simple moving average is $146.47.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Sunday, October 18th. The company reported $2.20 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.98 by $0.22. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. The business had revenue of $21.08 billion for the quarter, compared to analysts’ expectations of $20.15 billion. During the same quarter in the previous year, the business posted $2.12 EPS. Johnson & Johnson’s revenue for the quarter was up 1.7% on a year-over-year basis. On average, research analysts expect that Johnson & Johnson will post 7.99 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a dividend of $1.01 per share. This represents a $4.04 annualized dividend and a dividend yield of 2.81%. The ex-dividend date is Monday, November 23rd. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.54%.
In other news, EVP Kathryn E. Wengel sold 16,115 shares of Johnson & Johnson stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the transaction, the executive vice president now owns 66,658 shares in the company, valued at approximately $10,233,336.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.27% of the company’s stock.
Johnson & Johnson Profile
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
See Also: Does the Dogs of the Dow strategy work?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.